Navigation Links
AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
Date:4/20/2009

-- Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries --

DENVER, April 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL in late stage pre-clinical studies, according to research conducted at InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology. The potency was achieved with comparable safety even at levels one hundred times that required for therapeutic efficacy, according to several studies presented at the American Association of Cancer Research (AACR) 100th Annual Meeting this past weekend. DXL625 is designed to bind CD20, a protein receptor expressed on normal B cells and over-expressed on cancerous B cells.

InNexus has previously announced that the United States Food and Drug Administration had completed its comprehensive review of the development plans for DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL). InNexus' submission included detailed information on plans for a Phase I clinical program, preclinical pharmacology and toxicology data and its current manufacturing plans. The FDA noted at the time that the plans were suitable for the manufacture of Phase I product of DXL625 onsite at InNexus.

"The studies are an important validation of our core drug discovery platform and confirm our ability to significantly advance the state of the art in developing potentially superior biologics for major medical and commercial opportunities," said Jeff Morhet, Chairman and CEO at InNexus.

InNexus and institutional researchers author
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fralex reaches 100th patient milestone in fibromyalgia study
2. WolfPAC(sm) Integrated Risk Management Announces 100th Sale
3. eRT Completes Milestone 100th Thorough QT Study
4. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
5. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
6. Sinovac Announces Postponement of Annual General Meeting
7. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
8. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
10. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
11. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
... Pasteuria Bioscience announced that it has received registration ... Pasteuria usgae . This is a critical step towards ... bacteria prevalent in soil that have long been recognized as ... , "We,re very pleased to receive this EPA registration," ...
... STOCKHOLM, June 8 Diamyd Medical reported today,that the company ... to include children with type 1 diabetes from 10 years,of ... vaccine Diamyd(R). , (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ... conducting two parallel phase III studies, one in,Europe and one ...
... Through One Year , , HERZLIYA, Israel and SKILLMAN, ... U.S. Food and Drug Administration (FDA) approved a labeling supplement ... EVOLENCE(R), a collagen-based dermal filler for the correction of moderate ... , , To view the Multimedia News Release, go ...
Cached Biology Technology:Pasteuria Bioscience Receives EPA Registration for Nematode Control 2Diamyd(R) Phase III Study Approved for Younger Patients in the US 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 3Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 4
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
(Date:7/29/2014)... the climate warms and sea ice retreats, the North ... of increasingly open water which is predicted to extend ... this century. Storms thus have the potential to create ... new and unpredictable element to the region. , A University ... in the middle of the Arctic Ocean, and detected ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... engineers at Purdue University have developed a new method ... and they are proposing the creation of mobile processing ... fuels. "What,s important is that you can ... chips, switch grass, corn stover, rice husks, wheat straw ...
... tract is a teeming mass of hundreds of types of ... help us digest food and keep bad bacteria in check. ... receptor is a key player amid the gut bacteria ... helping to govern their activity, responding to their cues, and ...
... calling on policymakers to encourage the transition from coal-based electricity ... carbon tax. Such a mechanism would help limit carbon ... Change Conference in Copenhagen last December, the United States pledged ... by 17 percent by 2020. Dagobert Brito, the ...
Cached Biology News:New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 2Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 3Researchers calculate the cost of CO2 emissions, call for carbon tax 2
... (1995) This volume provides excellent ... for the study of major HIV proteins ... ribonuclease H, integrase and protease. Expression of ... Tat and Rev assays; HIV/CD4 interactions; transient ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: